TY - JOUR
T1 - Intraoperative imaging in ovarian cancer
T2 - Fact or fiction?
AU - Crane, Lucia M.A.
AU - Van Oosten, Marleen
AU - Pleijhuis, Rick G.
AU - Motekallemi, Arash
AU - Dowdy, Sean C.
AU - Cliby, William A.
AU - Van Der Zee, Ate G.J.
AU - Van Dam, Gooitzen M.
PY - 2011/7
Y1 - 2011/7
N2 - Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.
AB - Tumor-targeted fluorescence imaging for cancer diagnosis and treatment is an evolving field of research that is on the verge of clinical implementation. As each tumor has its unique biologic profile, selection of the most promising targets is essential. In this review, we focus on target finding in ovarian cancer, a disease in which fluorescence imaging may be of value in both adequate staging and in improving cytoreductive efforts, and as such may have a beneficial effect on prognosis. Thus far, tumor-targeted imaging for ovarian cancer has been applied only in animal models. For clinical implementation, the five most prominent targets were identified: folate receptor α, vascular endothelial growth factor, epidermal growth factor receptor, chemokine receptor 4, and matrix metalloproteinase. These targets were selected based on expression rates in ovarian cancer, availability of an antibody or substrate aimed at the target approved by the Food and Drug Administration, and the likelihood of translation to human use. The purpose of this review is to present requirements for intraoperative imaging and to discuss possible tumor-specific targets for ovarian cancer, prioritizing for targets with substrates ready for introduction into the clinic.
UR - http://www.scopus.com/inward/record.url?scp=79959752763&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959752763&partnerID=8YFLogxK
U2 - 10.2310/7290.2011.00004
DO - 10.2310/7290.2011.00004
M3 - Article
C2 - 21521557
AN - SCOPUS:79959752763
SN - 1535-3508
VL - 10
SP - 248
EP - 257
JO - Molecular Imaging
JF - Molecular Imaging
IS - 4
ER -